Develops oral antibiotics for urinary tract infections.
Jun 2026Revenue $47.0M/yrExpenses $41.0M/yr
No trend
Figures by year
Is Spero Therapeutics profitable?
Yes. In the 12 months to Jun 2026, revenue was $47.0M and expenses $41.0M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $66.8M | $60.5M | $6.31M |
| Dec 2024 | $48.0M | $121M | −$73.4M |
| Dec 2023 | $104M | $82.3M | $21.5M |
| Dec 2022 | $53.5M | $95.7M | −$42.2M |
| Dec 2021 | $18.3M | $106M | −$88.0M |
| Dec 2020 | $9.33M | $88.4M | −$79.1M |
| Dec 2019 | $18.1M | $81.4M | −$63.2M |
| Dec 2018 | $3.97M | $46.8M | −$42.8M |
| Dec 2017 | $1.98M | $43.7M | −$41.7M |
| Dec 2016 | $335K | $33.6M | −$33.2M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.